This study was designed to evaluate the interaction between total adiponectin (ADPN)
and metabolic syndrome (MetS) on cardiac changes in 135 subjects with and without
MetS, subgrouped according to normal or low ADPN. Left ventricular internal diameter
(LVID/h), LV mass (LVM), LVM index (LVMI), interventricular septal thickness (IVST),
relative wall thickness (RWT) and LV ejection fraction (EF) by echocardiography and
diastolic parameters, by pulsed-wave Doppler were calculated.
BMI, LVM, LVMI, LVID/h, IVST and RWT values were significantly (p<0.05) higher in
both groups with low ADPN. Prevalence of left ventricular hypertrophy (p<0.001) and
coronary artery disease (p<0.01) was significantly higher in both low ADPN groups.
LVMI correlated directly with BMI (p<0.001), (p<0.001), MetS (p<0.001) and inversely
with ADPN (p<0.0001). ADPN and BMI resulted independently associated with LVMI.
In conclusion, our data suggest that hypoadiponectinemia might be considered a novel
“cardiometabolic biomarker”. Accordingly, circulating ADPN might become a new
target in the management of cardiometabolic syndrome
